Ketamine for Depression: An MRI Study
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Hamilton Depression Rating Scale (HDRS) From Baseline/Minute 0 to 4 Hours Post-infusion. |
-9.625 | <0.01 sig |
| SECONDARY Percent Change in Tissue Fractional Anisotropy Quantification (Left Inferior Longitudinal Fasciculus) |
.901 | 0.048 sig |
| SECONDARY Percent Change in Tissue Fractional Anisotropy Quantification (Right Inferior Longitudinal Fasciculus) |
1.247 | 0.003 sig |
| SECONDARY Percent Change in Tissue Fractional Anisotropy Quantification (Left Superior Longitudinal Fasciculus) |
.696 | .0499 sig |
| SECONDARY Percent Change in Tissue Fractional Anisotropy Quantification (Right Uncinate Fasciculus) |
1.158 | 0.038 sig |
Eligibility Criteria
Inclusion Criteria: Patients with Depression
Patients will:
- be 18-64 years old,
- read, understand, and provide written informed consent in English,
- meet criteria for a primary psychiatric diagnosis of major depressive disorder for ≥ 4 weeks,
- have a history of ≥1 failed medication trial during the current depression
- be on a stable antidepressant and psychotherapy regimen for ≥28 days,
- maintain a treating doctor who is in agreement with study participation,
- have a reliable chaperone accompany them home following the completion of the ketamine infusion day,
- be generally healthy, as assessed by medical history, physical examination (including vital signs), clinical laboratory evaluations, and electrocardiogram (EKG),
- be of non-childbearing potential or use of an acceptable form of birth control (females only),
- be right handed.
Exclusion Criteria: Patients with Depression
Patients will be excluded if any of the following criteria are met:
- delirium or dementia diagnosis, 2) unstable medical illness or clinically significant laboratory results, 3) history of clinically significant cardiovascular disease or electrocardiogram (EKG) findings, or medical conditions that put the patient at risk for possible cardiac side effects or alter brain morphology (e.g., traumatic brain injury), 4) history of multiple adverse drug reactions, 5) current/past history of psychotic disorders, 6) active substance use disorders (except nicotine and caffeine) within the past six months or past history of ketamine/PCP abuse, 7) requirement of excluded medications that may interact with ketamine, 8) weigh >250 lbs., 9) pregnancy, breastfeeding, or unacceptable means of birth control (females only) 10) presence of MRI contraindications (e.g., presence of metallic (ferromagnetic) implants (e.g., heart pacemaker, aneurysm clips)), 11) current serious suicidal or homicidal risk, or 12) concurrent participation in other research studies.
---------------------------------------------------------------------------------------
Inclusion Criteria: Healthy Controls
Healthy Controls will:
- be 18-64 years old,
- read, understand, and provide written informed consent in English,
- have a reliable chaperone accompany them home following the completion of the ketamine infusion day,
- be generally healthy, as assessed by medical history, physical examination (including vital signs), clinical laboratory evaluations, and electrocardiogram (EKG),
- be of non-childbearing potential or use of an acceptable form of birth control (females only), and
- be right handed.
Exclusion Criteria: Healthy Controls
Healthy controls will be excluded if any of the following criteria are met:
- current or past psychiatric diagnosis (excluding phobias), including alcohol or substance abuse or dependence diagnosis (except for nicotine or caffeine),
- presence of MRI contraindications (e.g., presence of metallic (ferromagnetic) implants (e.g., heart pacemaker, aneurysm clips)),
- presence of medical illness likely to alter brain morphology and/or physiology (e.g., traumatic brain injury),
- requirement of excluded medications that may interact with ketamine,
- presence of psychiatric disorders in first-degree relatives,
- pregnancy, breastfeeding, or unacceptable means of birth control (females only), or
- weight >250 lbs.
Data sourced from ClinicalTrials.gov (NCT02544607). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.